The influence of concurrent chemoradiotherapy on survival for patients of different ages with stage Ⅳ non-small cell lung cancer——reanalysis of two prospective studies
10.3760/cma.j.issn.1004-4221.2019.04.004
- VernacularTitle:同期放化疗对不同年龄Ⅳ期非小细胞肺癌生存影响——两项前瞻性研究再分析
- Author:
Weixu FU
1
;
Weiwei OUYANG
;
Shengfa SU
;
Zhu MA
;
Qingsong LI
;
Yichao GENG
;
Daxian LUO
;
Wengang YANG
;
Yinxiang HU
;
Huiqin LI
;
Zhixu HE
;
Bing LU
Author Information
1. 贵州医科大学附属医院肿瘤科贵州医科大学肿瘤学教研室
- Keywords:
Lung neoplasm/three-dimensional radiotherapy;
Prognosis;
Adverse event
- From:
Chinese Journal of Radiation Oncology
2019;28(4):262-267
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the survival and toxicity after concurrent chemoradiotherapy in patients of different ages with stage Ⅳ non-small cell lung cancer (NSCLC).Methods Clinical data of 282 NSCLC patients in two prospective studies were retrospectively analyzed,who completed the protocol (at least 2 cycles of chemotherapy and thoracic radiation doses of ≥36 Gy).Among them,44 patients were assigned into in the young group (≤ 45 years old),161 patients in the middle-age group (46-64 years old) and 77 patients in the elderly group (≥ 65 years old).The clinical characteristics of patients among different groups were analyzed by x2 test.The overall survival (OS) was calculated by Kaplan-Meier method.Stratified analysis was performed by Log-rank test.Multi-factor prognosis analysis was conducted by Cox's proportional hazards regression model.Results The incidence of NSCLC in the male patients in the elderly group was higher than that in the middle-age and young groups.The 1-,2-,3-and 5-year OS did not significantly differ among different groups (P=0.810).The OS did not significantly differ among patients of the same gender,pathological type,T stage,N stage,metastasis status,same chemotherapy cycle,primary tumor dose and comprehensive treatment and short-term response (all P＞0.05).The incidence of adverse events did not considerably differ among different groups.Multivariate analysis demonstrated that age was not an independent factor for survival (P＞ O.05).Conclusion Patients of different ages with stage Ⅳ NSCLC obtain similar survival benefits and adverse events after concurrent chemoradiotherapy.
